Industry Response To Brexit Survey Key For Future Planning, Says EMA
Executive Summary
Sponsors of centrally authorized medicines in the EU are being urged to respond to a survey by the European Medicines Agency aimed at gauging industry's preparedness for Brexit. Companies have until Feb. 9 to complete survey, which the EMA says is critical to help with resource planning and ensuring a smooth transition.
You may also be interested in...
EMA To Contact Sponsors Of Over 100 Drugs At Risk Of Shortage Post Brexit
The European Medicines Agency’s survey on industry’s preparedness for Brexit has raised serious concerns about the continued supply of 108 drugs that have manufacturing operations based solely in the UK.
Will A Brexit Transition Period Meet The Needs Of UK Industry?
As negotiators prepare to discuss a Brexit “transition period,” the UK and European parliaments have again been debating options for addressing the potential impact on the pharmaceutical supply chain.
Dutch Delegation Promises ‘Seamless’ Transition To EMA’s New Home
Dutch officials took part in the December meeting of the EMA management board and presented details of their plans for the agency’s relocation to Amsterdam. The board also adopted the 2018 work program and budget, which allow for a 6.8% rise in fee-related revenue next year, and said phase 2 of the Brexit business continuity plan would begin in January.